AzTrials
AzTrials

Cardiovascular DiseasePhase 4TNTNCT00327691

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

A Phase 4 study testing Atorvastatin in people with Cardiovascular Disease and Cerebrovascular Accident, run by Pfizer at 314 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Read more about this study

Who is it for?
Ages 35 to 75 years
What is being tested?
Atorvastatin
How many people
8,600 participants
Where
314 sitesin 15 countries
Study dates
Apr 1998to Aug 2004
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women age 35-75 who have evident CHD

Who cannot join

  • Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

Trial locations and contacts

314 sites in 15 countries.

314 sites in 15 countries

United States181 sites

  • Pfizer Investigational Site

    Alabaster, Alabama, 35007

  • Pfizer Investigational Site

    Albany, New York, 12208

  • Pfizer Investigational Site

    Allentown, Pennsylvania, 18102

  • Pfizer Investigational Site

    Allentown, Pennsylvania, 18106-0880

  • Pfizer Investigational Site

    Asheville, North Carolina, 28803

  • Pfizer Investigational Site

    Atlanta, Georgia, 30309

  • Pfizer Investigational Site

    Aurora, Colorado, 80012

  • Pfizer Investigational Site

    Austin, Texas, 78756

  • Pfizer Investigational Site

    Baltimore, Maryland, 21201

  • Pfizer Investigational Site

    Baltimore, Maryland, 21204

  • Pfizer Investigational Site

    Baltimore, Maryland, 21205

  • Pfizer Investigational Site

    Baltimore, Maryland, 21208

  • Pfizer Investigational Site

    Baltimore, Maryland, 21218

  • Pfizer Investigational Site

    Baltimore, Maryland, 21224

  • Pfizer Investigational Site

    Baltimore, Maryland, 21228

  • Pfizer Investigational Site

    Baltimore, Maryland, 21229

  • Pfizer Investigational Site

    Baltimore, Maryland, 21237

  • Pfizer Investigational Site

    Baltimore, Maryland, 21287

  • Pfizer Investigational Site

    Beachwood, Ohio, 44122

  • Pfizer Investigational Site

    Beech Grove, Indiana, 46107

  • Pfizer Investigational Site

    Bel Air, Maryland, 21014

  • Pfizer Investigational Site

    Berwyn, Illinois, 60402

  • Pfizer Investigational Site

    Birmingham, Alabama, 35205-4785

  • Pfizer Investigational Site

    Birmingham, Alabama, 35213

  • Pfizer Investigational Site

    Birmingham, Alabama, 35294-2041

  • Pfizer Investigational Site

    Blue Island, Illinois, 60406

  • Pfizer Investigational Site

    Boston, Massachusetts, 02111

  • Pfizer Investigational Site

    Boston, Massachusetts, 02215

  • Pfizer Investigational Site

    Bridgeport, Connecticut, 06610

  • Pfizer Investigational Site

    Brooklyn, New York, 11203

  • Pfizer Investigational Site

    Burbank, California, 91505

  • Pfizer Investigational Site

    Burlington, Massachusetts, 1805

  • Pfizer Investigational Site

    Burlington, Vermont, 05401

  • Pfizer Investigational Site

    Camp Pendleton, California, 92055

  • Pfizer Investigational Site

    Canton, Georgia, 30114

  • Pfizer Investigational Site

    Charleston, South Carolina, 29403

  • Pfizer Investigational Site

    Chicago, Illinois, 60610

  • Pfizer Investigational Site

    Chicago, Illinois, 60611

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45219

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45229

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45246

  • Pfizer Investigational Site

    Clearwater, Florida, 33756

  • Pfizer Investigational Site

    Cleveland, Ohio, 44106-5038

  • Pfizer Investigational Site

    Cleveland, Ohio, 44195

  • Pfizer Investigational Site

    Columbus, Ohio, 43210

  • Pfizer Investigational Site

    Columbus, Ohio, 43221

  • Pfizer Investigational Site

    Dallas, Texas, 75235

  • Pfizer Investigational Site

    Dallas, Texas, 75246

  • Pfizer Investigational Site

    Dallas, Texas, 75390-9047

  • Pfizer Investigational Site

    Dearborn, Michigan, 48126

  • Pfizer Investigational Site

    Denton, Texas, 76204

  • Pfizer Investigational Site

    Denver, Colorado, 80203

  • Pfizer Investigational Site

    Denver, Colorado, 80218

  • Pfizer Investigational Site

    Denver, Colorado, 80220

  • Pfizer Investigational Site

    Des Moines, Iowa, 50314

  • Pfizer Investigational Site

    Detroit, Michigan, 48202

  • Pfizer Investigational Site

    Du Quoin, Illinois, 62832

  • Pfizer Investigational Site

    Duluth, Minnesota, 55805

  • Pfizer Investigational Site

    Durham, North Carolina, 27710

  • Pfizer Investigational Site

    Eden, North Carolina, 27288

  • Pfizer Investigational Site

    Edgewood, Kentucky, 41017

  • Pfizer Investigational Site

    Edina, Minnesota, 55435

  • Pfizer Investigational Site

    Erlanger, Kentucky, 41018

  • Pfizer Investigational Site

    Eugene, Oregon, 97401

  • Pfizer Investigational Site

    Evanston, Illinois, 60201

  • Pfizer Investigational Site

    Evansville, Indiana, 47710

  • Pfizer Investigational Site

    Farmington Hill, Michigan, 48336

  • Pfizer Investigational Site

    Fort Wayne, Indiana, 46805

  • Pfizer Investigational Site

    Fort Wayne, Indiana, 46825

  • Pfizer Investigational Site

    Fresno, California, 93703

  • Pfizer Investigational Site

    Gainsville, Florida, 32608

  • Pfizer Investigational Site

    Gainsville, Florida, 32610

  • Pfizer Investigational Site

    Hartford, Connecticut, 06102

  • Pfizer Investigational Site

    Hawthorne, New York, 10535

  • Pfizer Investigational Site

    Hollywood, Florida, 33021

  • Pfizer Investigational Site

    Hoover, Alabama, 35216

  • Pfizer Investigational Site

    Houston, Texas, 77030

  • Pfizer Investigational Site

    Inverness, Florida, 34452

  • Pfizer Investigational Site

    Iowa City, Iowa, 52242

  • Pfizer Investigational Site

    Jeffersonville, Indiana, 47130

  • Pfizer Investigational Site

    Kansas City, Kansas, 66160-7200

  • Pfizer Investigational Site

    Kansas City, Missouri, 64111

  • Pfizer Investigational Site

    Kettering, Ohio, 45429-1221

  • Pfizer Investigational Site

    La Jolla, California, 92037

  • Pfizer Investigational Site

    Lackland Air Force Base, Texas, 78236-5300

  • Pfizer Investigational Site

    Lake Forest, Illinois, 60045

  • Pfizer Investigational Site

    Lakeland, Florida, 33805

  • Pfizer Investigational Site

    Lansdale, Pennsylvania, 19446

  • Pfizer Investigational Site

    Lathe, Kansas, 66061

  • Pfizer Investigational Site

    Lehighton, Pennsylvania, 18235

  • Pfizer Investigational Site

    Loma Linda, California, 92354

  • Pfizer Investigational Site

    Lorain, Ohio, 44053

  • Pfizer Investigational Site

    Los Angeles, California, 90017-2395

  • Pfizer Investigational Site

    Los Angeles, California, 90048

  • Pfizer Investigational Site

    Louisville, Kentucky, 40202

  • Pfizer Investigational Site

    Manchester, New Hampshire, 03102

  • Pfizer Investigational Site

    Manlius, New York, 13104

  • Pfizer Investigational Site

    Maplewood, Minnesota, 55109

  • Pfizer Investigational Site

    Marion, Illinois, 62959

  • Pfizer Investigational Site

    Marrero, Louisiana, 70072

  • Pfizer Investigational Site

    Memphis, Tennessee, 38104

  • Pfizer Investigational Site

    Memphis, Tennessee, 38105

  • Pfizer Investigational Site

    Memphis, Tennessee, 38119-5209

  • Pfizer Investigational Site

    Memphis, Tennessee, 38128

  • Pfizer Investigational Site

    Mesa, Arizona, 85202

  • Pfizer Investigational Site

    Mesa, Arizona, 85206

  • Pfizer Investigational Site

    Miami, Florida, 33173

  • Pfizer Investigational Site

    Miami, Florida, 33176

  • Pfizer Investigational Site

    Milwaukee, Wisconsin, 53295

  • Pfizer Investigational Site

    Minneapolis, Minnesota, 55455

  • Pfizer Investigational Site

    Modesto, California, 95350

  • Pfizer Investigational Site

    Montgomery, Alabama, 36117

  • Pfizer Investigational Site

    Nashville, Tennessee, 37205

  • Pfizer Investigational Site

    Nashville, Tennessee, 37232-6300

  • Pfizer Investigational Site

    New Britain, Connecticut, 06053

  • Pfizer Investigational Site

    New Brunswick, New Jersey, 08901

  • Pfizer Investigational Site

    New Orleans, Louisiana, 70112

  • Pfizer Investigational Site

    New Orleans, Louisiana, 70121

  • Pfizer Investigational Site

    New York, New York, 10021

  • Pfizer Investigational Site

    New York, New York, 10029

  • Pfizer Investigational Site

    New York, New York, 10032

  • Pfizer Investigational Site

    Newark, Delaware, 19718

  • Pfizer Investigational Site

    Ocala, Florida, 34474

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73104

  • Pfizer Investigational Site

    Orlando, Florida, 32803

  • Pfizer Investigational Site

    Overland Park, Kansas, 66213

  • Pfizer Investigational Site

    Papillion, Nebraska, 68046

  • Pfizer Investigational Site

    Pasadena, California, 91105

  • Pfizer Investigational Site

    Pawtucket, Rhode Island, 02860

  • Pfizer Investigational Site

    Pekin, Illinois, 61554

  • Pfizer Investigational Site

    Peoria, Illinois, 61603

  • Pfizer Investigational Site

    Peoria, Illinois, 61614

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19104

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19107

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania, 15213

  • Pfizer Investigational Site

    Port Charlotte, Florida, 33952

  • Pfizer Investigational Site

    Portland, Maine, 04102

  • Pfizer Investigational Site

    Portland, Oregon, 97210

  • Pfizer Investigational Site

    Portland, Oregon, 97216

  • Pfizer Investigational Site

    Providence, Rhode Island, 02906

  • Pfizer Investigational Site

    Rancho Mirage, California, 92270

  • Pfizer Investigational Site

    Richmond, Virginia, 23249

  • Pfizer Investigational Site

    Richmond, Virginia, 23298

  • Pfizer Investigational Site

    Rochester, New York, 14607

  • Pfizer Investigational Site

    Rochester, New York, 14618

  • Pfizer Investigational Site

    Rochester, New York, 14621

  • Pfizer Investigational Site

    Saint Paul, Minnesota, 55102

  • Pfizer Investigational Site

    Salt Lake City, Utah, 84124

  • Pfizer Investigational Site

    San Antonio, Texas, 78229

  • Pfizer Investigational Site

    San Diego, California, 92134-3303

  • Pfizer Investigational Site

    San Francisco, California, 94143-0130

  • Pfizer Investigational Site

    San Francisco, California, 94143-0326

  • Pfizer Investigational Site

    Sandusky, Ohio, 44870

  • Pfizer Investigational Site

    Santa Rosa, California, 95403

  • Pfizer Investigational Site

    Sarasota, Florida, 34239

  • Pfizer Investigational Site

    Scottsburg, Indiana, 47170

  • Pfizer Investigational Site

    Seattle, Washington, 98104

  • Pfizer Investigational Site

    Sellersville, Pennsylvania, 18960

  • Pfizer Investigational Site

    Sioux Falls, South Dakota, 57105

  • Pfizer Investigational Site

    Sioux Falls, South Dakota, 57108

  • Pfizer Investigational Site

    St Louis, Missouri, 63104

  • Pfizer Investigational Site

    St Louis, Missouri, 63110-0205

  • Pfizer Investigational Site

    St Louis, Missouri, 63110

  • Pfizer Investigational Site

    St Louis, Missouri, 63117

  • Pfizer Investigational Site

    St Louis, Missouri, 63141

  • Pfizer Investigational Site

    Stanford, California

  • Pfizer Investigational Site

    Sterling Heights, Michigan, 48310

  • Pfizer Investigational Site

    Stuart, Florida, 34996

  • Pfizer Investigational Site

    Syracuse, New York, 13202

  • Pfizer Investigational Site

    Syracuse, New York, 13210

  • Pfizer Investigational Site

    Tamarac, Florida, 33321

  • Pfizer Investigational Site

    The Villages, Florida, 32159

  • Pfizer Investigational Site

    Tulsa, Oklahoma, 74133

  • Pfizer Investigational Site

    Tulsa, Oklahoma, 74136-1920

  • Pfizer Investigational Site

    Tulsa, Oklahoma, 74136

  • Pfizer Investigational Site

    Valhalla, New York, 10595

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20037

  • Pfizer Investigational Site

    West Bloomfield, Michigan, 48322

  • Pfizer Investigational Site

    Westminster, Maryland, 21157

  • Pfizer Investigational Site

    Wichita, Kansas, 67220

  • Pfizer Investigational Site

    Winston-Salem, North Carolina, 27157

Other trials in United States

Canada22 sites

  • Pfizer Investigational Site

    Calgary, Alberta, T2E 7C5

  • Pfizer Investigational Site

    Calgary, Alberta, T2N 4N1

  • Pfizer Investigational Site

    Chicoutimi, Quebec, G7H 5H6

  • Pfizer Investigational Site

    Edmonton, Alberta, T5R 4H5

  • Pfizer Investigational Site

    Edmonton, Alberta, T6G 2B7

  • Pfizer Investigational Site

    Greater Sudbury, Ontario, P3E 1B8

  • Pfizer Investigational Site

    Halifax, Nova Scotia, B3H 3A7

  • Pfizer Investigational Site

    Hamilton, Ontario, L8L 2X2

  • Pfizer Investigational Site

    London, Ontario, N6A 4G5

  • Pfizer Investigational Site

    Montreal, Quebec, H1T 1C8

  • Pfizer Investigational Site

    Montreal, Quebec, H2W 1R7

  • Pfizer Investigational Site

    Montreal, Quebec, H3A 1A1

  • Pfizer Investigational Site

    Nanaimo, British Columbia, V9S 2B8

  • Pfizer Investigational Site

    Ottawa, Ontario, K1Y 4W7

  • Pfizer Investigational Site

    Québec, Quebec, G1R 2J6

  • Pfizer Investigational Site

    Sherbrooke, Quebec, J1H 5N4

  • Pfizer Investigational Site

    St-foy, Quebec, G1V 4G2

  • Pfizer Investigational Site

    St. John's, Newfoundland and Labrador, A1B 3V6

  • Pfizer Investigational Site

    Toronto, Ontario, M5C 2T2

  • Pfizer Investigational Site

    Vancouver, British Columbia, V6R 1Y6

  • Pfizer Investigational Site

    Victoria, British Columbia, V8T 5G4

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1R9

Other trials in Canada

United Kingdom17 sites

  • Pfizer Investigational Site

    Aldershot, HAMPSHIRE, GU11 3RB

  • Pfizer Investigational Site

    Barnet, EN5 3DJ

  • Pfizer Investigational Site

    Blackpool, LANCASHIRE, FY3 8NR

  • Pfizer Investigational Site

    Coventry, West Midlands, CV1 4FH

  • Pfizer Investigational Site

    Coventry, WEST Midlands, CV2 2DX

  • Pfizer Investigational Site

    Farnborough, KENT, BR6 7AR

  • Pfizer Investigational Site

    Glasgow, G11 6NT

  • Pfizer Investigational Site

    Leicester, LEICESTERSHIRE, LE3 9QP

  • Pfizer Investigational Site

    London, GREATER LONDON, E2 9JX

  • Pfizer Investigational Site

    London, GREATER LONDON, NW10 7NS

  • Pfizer Investigational Site

    London, GREATER LONDON, SW17 0RE

  • Pfizer Investigational Site

    London, MIDDLESEX, HA8 0AD

  • Pfizer Investigational Site

    London, E1 1BB

  • Pfizer Investigational Site

    London, NW3 2PF

  • Pfizer Investigational Site

    Paisley, P1 1HR

  • Pfizer Investigational Site

    Romford, ESSEX, RM7 OBE

  • Pfizer Investigational Site

    Swindon, Wiltshire, SN3 6BB

Other trials in United Kingdom

Australia14 sites

  • Pfizer Investigational Site

    Adelaide, South Australia, 5000

  • Pfizer Investigational Site

    Auchenflower, Queensland, 4066

  • Pfizer Investigational Site

    Bedford Park, South Australia, 5042

  • Pfizer Investigational Site

    Brisbane, Queensland, 4029

  • Pfizer Investigational Site

    Chermside, Queensland, 4032

  • Pfizer Investigational Site

    Clayton, Victoria, 3168

  • Pfizer Investigational Site

    Greenslopes, Queensland, 4130

  • Pfizer Investigational Site

    Herston, Queensland, 4029

  • Pfizer Investigational Site

    Hobart, Tasmania, 7000

  • Pfizer Investigational Site

    Milton, Queensland, 4064

  • Pfizer Investigational Site

    Nedlands, Western Australia, 6009

  • Pfizer Investigational Site

    Parkville, Victoria, 3050

  • Pfizer Investigational Site

    Prahran, Victoria, 3181

  • Pfizer Investigational Site

    St Leonards, New South Wales, 2065

Other trials in Australia

Netherlands14 sites

  • Pfizer Investigational Site

    's-Hertogenbosch, 5211 NL

  • Pfizer Investigational Site

    Alkmaar, 1815 JD

  • Pfizer Investigational Site

    Amersfoort, 3818 ES

  • Pfizer Investigational Site

    Amsterdam, 1105 AZ

  • Pfizer Investigational Site

    Breda, 4818 CK

  • Pfizer Investigational Site

    Eindhoven, 5623 EJ

  • Pfizer Investigational Site

    Enschede, 7513 ER

  • Pfizer Investigational Site

    Groningen, 9713 GZ

  • Pfizer Investigational Site

    Groningen, 9728 NZ

  • Pfizer Investigational Site

    Leiden, 2333 ZA

  • Pfizer Investigational Site

    Nieuwegein, 3435 CM

  • Pfizer Investigational Site

    Nijmegen, 6532 SZ

  • Pfizer Investigational Site

    Zwolle, 8011 JW

  • Pfizer Investigational Site

    Zwolle, 8025 AB

Other trials in Netherlands

France13 sites

  • Pfizer Investigational Site

    Agen, 47000

  • Pfizer Investigational Site

    Bordeaux, 33000

  • Pfizer Investigational Site

    Brest, 29200

  • Pfizer Investigational Site

    Clermont-Ferrand, 63003

  • Pfizer Investigational Site

    Lyon, 69003

  • Pfizer Investigational Site

    Marseille, 13915 Cedex 20

  • Pfizer Investigational Site

    Paris, 75230

  • Pfizer Investigational Site

    Pessac, Cedex, 33604

  • Pfizer Investigational Site

    Rennes, 35033

  • Pfizer Investigational Site

    Roubaix, 59056

  • Pfizer Investigational Site

    Strasbourg, 67091

  • Pfizer Investigational Site

    Toulouse, 31059

  • Pfizer Investigational Site

    Toulouse, 31400

Other trials in France

Spain13 sites

  • Pfizer Investigational Site

    Barcelona, 08035

  • Pfizer Investigational Site

    Barcelona, 08036

  • Pfizer Investigational Site

    Córdoba, CORDOBA, 14004

  • Pfizer Investigational Site

    Donostia / San Sebastian, 20014

  • Pfizer Investigational Site

    Madrid, Madrid, 28007

  • Pfizer Investigational Site

    Madrid, 28029

  • Pfizer Investigational Site

    Madrid, 28040

  • Pfizer Investigational Site

    Madrid, 28041

  • Pfizer Investigational Site

    Santiago de Compostela, 15706

  • Pfizer Investigational Site

    Seville, Sevilla, 41009

  • Pfizer Investigational Site

    Seville, Sevilla, 41013

  • Pfizer Investigational Site

    Valladolid, 47011

  • Pfizer Investigational Site

    Zaragoza, 50009

Other trials in Spain

Belgium8 sites

  • Pfizer Investigational Site

    Aalst, 9300

  • Pfizer Investigational Site

    Antwerp, B-2020

  • Pfizer Investigational Site

    Genk, 3600

  • Pfizer Investigational Site

    Genk, B-3600

  • Pfizer Investigational Site

    Godinne, 5530

  • Pfizer Investigational Site

    Leuven, 3000

  • Pfizer Investigational Site

    Lommel, 3920

  • Pfizer Investigational Site

    Neerpelt, 3910

Other trials in Belgium

Germany7 sites

  • Pfizer Investigational Site

    Berlin, 13353

  • Pfizer Investigational Site

    Berlin, 13439

  • Pfizer Investigational Site

    Essen, 45329

  • Pfizer Investigational Site

    Hamburg, 20246

  • Pfizer Investigational Site

    Schwerte, D-58239

  • Pfizer Investigational Site

    Tostedt, 21255

  • Pfizer Investigational Site

    Würzburg, 97070

Other trials in Germany

Italy7 sites

  • Pfizer Investigational Site

    Bologna, 40138

  • Pfizer Investigational Site

    Bologna, 40139

  • Pfizer Investigational Site

    Cuneo, 12100

  • Pfizer Investigational Site

    Florence, 50134

  • Pfizer Investigational Site

    Naples, 80131

  • Pfizer Investigational Site

    Rome, 00184

  • Pfizer Investigational Site

    Udine, 33100

Other trials in Italy

South Africa6 sites

  • Pfizer Investigational Site

    Bloemfontein, 9301

  • Pfizer Investigational Site

    Cape Town, 7405

  • Pfizer Investigational Site

    Cape Town, 7500

  • Pfizer Investigational Site

    Johannesburg, Gauteng, 2193

  • Pfizer Investigational Site

    Parow, 7505

  • Pfizer Investigational Site

    Sunninghill, Gauteng, 2157

Other trials in South Africa

Switzerland5 sites

  • Pfizer Investigational Site

    Bern, 3010

  • Pfizer Investigational Site

    Geneva, CH-1211

  • Pfizer Investigational Site

    Lausanne, CH-1011

  • Pfizer Investigational Site

    Lugano, 6900

  • Pfizer Investigational Site

    Sankt Gallen, CH-9007

Other trials in Switzerland

Austria4 sites

  • Pfizer Investigational Site

    Feldkirch, A-6807

  • Pfizer Investigational Site

    Oberpullendorf, A-7350

  • Pfizer Investigational Site

    Vienna, 1100

  • Pfizer Investigational Site

    Vienna, A-1090

Other trials in Austria

Ireland2 sites

  • Pfizer Investigational Site

    Cork

  • Pfizer Investigational Site

    Dublin, D8

Other trials in Ireland

Location not given1 site

  • Pfizer Investigational Site

About this study

Official title: The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

Being tested
Atorvastatin
Keywords
Major cardiovascular event, Major Coronary event, Revascularization
Medical subject headings
Cardiovascular Diseases, Stroke, Coronary Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome is the time to occurrence of a major

  2. cardiovascular event, defined as the composite outcome of the

  3. following clinical endpoints

  4. CHD death

  5. Non-fatal/Non-procedure related MI

  6. Resuscitated cardiac arrest or fatal/non-fatal stroke

Secondary outcomes (7)

  1. The occurrence of the following clinical events

  2. Major coronary event (CHD death, non fatal myocardial infarction or resuscitated cardiac arrest)

  3. any coronary event (major coronary event or CABG

  4. PTCA, other revascularization procedure, procedure-related myocardial infarction, or documented angina)

  5. cerebrovascular event (fatal or non fatal stroke, TIA)

  6. peripheral vascular disease; hospitalization with primary diagnosis' of CHF

  7. any cardiovascular event (any of the above); and all-cause mortality.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2006 (estimated)
  2. Study startApr 1998
  3. Study completionAug 2004

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
8,600 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00327691
Sponsor's protocol ID
0981-117
Other IDs
A2581136
Acronym
TNT
Status last verified
May 2007
First submitted
16 May 2006
Last updated
3 May 2007
Results posted
No

Publications

  • Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17.

    PubMed 17084252

  • Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.

    PubMed 38018702

  • Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.

    PubMed 31020900

  • Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.

    PubMed 30571333

  • Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.

    PubMed 29622600

  • Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.

    PubMed 29618599

  • Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.

    PubMed 29358194

  • Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.

    PubMed 28573499

  • Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148.

    PubMed 28379800

  • Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.

    PubMed 28214794

  • Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.

    PubMed 27513651

  • Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.

    PubMed 25835440

  • Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014.

    PubMed 25531109

  • Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.

    PubMed 23674398

  • Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.

    PubMed 22576673

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Atorvastatin in people with Cardiovascular Disease and Cerebrovascular Accident, run by Pfizer at 314 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 May 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 314 sites in United States, Canada, United Kingdom, Australia, Netherlands and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome is the time to occurrence of a major. The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00327691, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2007.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in